New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs 5-Amino-1MQ

Pancragen vs 5-Amino-1MQ

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Fat Loss & Metabolic
5-Amino-1MQ
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
Half-Life
Short (minutes); sustained gene-regulatory effects
Estimated 4–8 hours
Admin Route
SubQ, Oral
Oral
Research
Typical Dose
10 mg per day
50–100 mg
Frequency
Daily for 10–30 days
Once to twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Raises intracellular NAD+ levels
  • Directly targets adipose tissue for fat reduction
  • Reduces fat cell size and differentiation
  • Increases basal metabolic rate
  • SIRT1 activation for metabolic regulation
  • No stimulant cardiovascular side effects
  • Synergistic with intermittent fasting and caloric restriction
  • May have anti-aging metabolic benefits
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally well-tolerated in available studies
  • Mild GI discomfort (rare)
  • Limited long-term human data
Stacks With